Incheon, Korea
Samsung broke ground in late May of 2011 on a $305 million biologics manufacturing plant in Incheon, Korea. The 274,000-sf complex will include a 30,000-litre cell culture vat and a laboratory for pharmaceutical and biosimilar research and development. Construction is expected to reach completion in 2012 with production commencing in early 2013. The biologics manufacturing plant will comply with the U.S. Food and Drug Administration’s current Good Manufacturing Practice (cGMP) protocols.
